# A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients

> **NCT02009397** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Louisville** · enrollment: 27 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** GM-CSF

## Key facts

- **NCT ID:** NCT02009397
- **Lead sponsor:** University of Louisville
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2021-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02009397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02009397, "A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02009397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*